Halo Neuroscience is a San Francisco, CA-based neuroscience and technology-driven human performance company that provides a neurostimulation headset designed to accelerate performance gains from physical training. The headset is used by elite customers including the US Olympic Ski Team, the San Francisco Giants and US Special Operations Forces. Led by CEO and co-founder Daniel Chao, the company plans to use its latest funding to expand globally and to develop and launch future products. On April 30, 2018, Halo raised US$1m in funding from Future Planet Capital. In January the company secured US$14m in Series B financing led by TPG, with additional participation from Xfund, Lux Capital and JAZZ Venture Partners. Halo Neuroscience makes a neurostimulation headset, Halo Sport, that targets the motor cortex to accelerate acquisition of muscle memory from athletic training. A twenty-minute "neuropriming" session induces temporary hyperplasticity, or "hyperlearning," optimizing neural pathways from the motor cortex to muscles. The product launched in 2016 and is used by organizations including the San Francisco Giants, the US Olympic Ski Team, and U.S. Special Operations Forces. The company was founded in 2013 and is led by co-founder Daniel Chao. In January 2018 Halo Neuroscience secured $13M in Series B financing. Investors in the round include TPG, Lux Capital, JAZZ Venture Partners and Xfund. Halo Neuroscience is a San Francisco, CA-based developer of a neurotechnology platform focused on athletic performance. The company is finalizing and launching Halo Sport, its first product that uses proprietary Neuropriming technology to improve the brain’s response to training and drive accelerated performance gains. Halo Sport is available to elite teams and organizations, with a limited consumer release scheduled to ship in Fall 2016. The company will use proceeds from its Series A to launch the product and expand operations. Halo Neuroscience was co-founded by Daniel Chao, MD, MS (CEO), Brett Wingeier, PhD (CTO), and Amol Sarva. The company raised $9M in Series A funding. Halo Neuroscience is developing a wearable device that applies electrical stimulation to the brain to "boost brain function" in both sick and healthy people. The company says the technology can accelerate learning and improve body movement control, though it has not specified which application it will pursue first. Founders include Stanford‑educated neuroscience researcher Dan Chao (CEO), engineer Brett Wingeier, and Amol Sarva, who brings consumer mobile and hardware experience. Halo closed a $1.5 million financing led by Marc Andreessen of Andreessen Horowitz and Jeff Clavier of SoftTech VC. The company plans to use the funding primarily to address intellectual property and safety issues with the U.S. Food and Drug Administration. The team emphasizes developing safe, regulated stimulation technology rather than making exaggerated claims about dramatic abilities.

Total raised

$25M

Funding rounds

4

Latest round

Equity

Latest activity

Apr 2018